All patients with inflammatory bowel disease should have bone density assessment: Con

Inflammatory Bowel Diseases

Volumn 7, Issue 2, 2001, Pages 163-167

  Leslie, William D ^a  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANOREXIA NERVOSA; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; FEMALE; GENERAL PRACTICE; HUMAN; MALABSORPTION; MALE; MORBIDITY; MORTALITY; NUTRITIONAL DEFICIENCY; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; SCREENING;

EID: 0034777299     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200105000-00013     Document Type: Article

References (63)

1. Development Committee of the National Osteoporosis Foundation. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis
2. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update
3. Corticosteroid osteoporosis: Practical implications of recent trials
4. Biphosphonates for steroid induced osteoporosis
5. Calcium and vitamin D for corticosteroid-induced osteoporosis
6. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis
7. Users' guides to the medical literature: XVII. How to use guidelines and recommendations about screening. Evidence-Based Medicine Working Group
8. Principles of screening
9. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study
10. Randomized controlled trial of faecal-occult-blood screening for colorectal cancer
11. Randomized study of screening for colorectal cancer with faecal-occult blood test
12. Prevention of colorectal cancer: Guidelines based on new data
13. Risk factors for hip fracture in white women
14. The role of clinical risk factors in the prediction of future fracture risk
15. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group
16. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study
17. Bone densitometry: The best way to detect osteoporosis and to monitor therapy
18. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
19. International collaboration in health technology assessment: A study of technologies used in management of osteoporosis
20. The effectiveness of bone density measurement and associated treatments for prevention of fractures. An international collaborative review
21. Inflammatory bowel disease and predisposition to osteopenia
22. Bone mineral density and body composition in patients with ulcerative colitis
23. Bone mineral density in patients with recently diagnosed inflammatory bowel disease
24. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: A case-control cross-sectional study of 113 patients
25. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease
26. Bone loss in patients with inflammatory bowel disease is less than expected: A follow-up study
27. Bone mineral content in patients with Crohn's disease
28. Determinants of bone loss from the femoral neck in women of different ages
29. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease
30. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
31. Bone mass, bone fragility, and the decision to treat
32. Esophagitis associated with the use of alendronate
33. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women
34. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study
35. Raloxifene: A review of its use in postmenopausal osteoporosis
36. The incidence of venous thromboembolic disease among patients with IBD: A population-based study
37. Complications of inflammatory bowel disease
38. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis
39. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: A population based study
40. Increased urinary N-telopeptide corss-linked type I collagen predicts bone loss in patients with inflammatory bowel disease
41. Osteoporosis and determinants of bone density in patients with Crohn's disease
42. Evolution of osteopenia in inflammatory bowel disease
43. Osteomalacia due to vitamin D depletion: A neglected consequence of intestinal malabsorption
44. Secondary osteoporosis: The potential relevance of leptin and low body weight
45. Mechanisms and treatment options for bone loss in anorexia nervosa
46. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea
47. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa
48. The importance of body weight history in the occurrence and recovery of osteoporosis in patients with anorexia nervosa: Evaluation by dual X-ray absorptiometry and bone metabolic markers
49. Osteopenia in anorexia nervosa: Specific mechanisms of bone loss
50. The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa
51. Osteoporosis and eating disorders
52. New approaches for interpreting projected bone densitometry data
53. Volumetric bone mineral density in normal subjects, aged 5-27 years
54. Comparison of areal and estimated volumetric bone mineral density values between older men and women
55. Differences in bone mineral in young Asian and Caucasian Americans may reflect differences in bone size
56. Whole body bone mineral content in healthy children and adolescents
57. Evolution of lumbar bone mineral content during adolescence and adulthood: A longitudinal study in 395 healthy females 10-24 years of age and 206 premenopausal women
58. On exposure to anorexia nervosa, the temporal variation in axial and appendicular skeletal development predisposes to site-specific deficits in bone size and density: A cross-sectional study
59. Nutritional issues in pediatric inflammatory bowel disease
60. Growth failure in pediatric inflammatory bowel disease
61. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis
62. Risk factors for low bone mineral density in children and young adults with Crohn's disease
63. Treatment of osteoporosis: Role of bone-forming agents